体内外因素对大鼠肝脏加工ADAMs的影响研究

ADAMs是近年发现的一个新的具有多个结构域和多种功能的蛋白质家族。本文多方面比较了大鼠实质肝细胞和非实质肝细胞的ADAMs与再生肝的ADAMs异同。检测多种因子对ADAMs体外加工的影响发现,活性的最适pH为3.5-4的酸性蛋白水解酶在细胞ADAMs降解加工中起关键作用;活性的最适pH为7.5-8.5的偏碱性蛋白酶在基质ADAMs降解加工中起重要作用;外源的胶原酶能高效降解75kDADAMs和140kDMDC15,可见,体内胶原酶样的蛋白水解酶是ADAMs降解加工的重要酶类;Fe^3 和Zn^2 等可在体外活化ADAMs的降解,看来,体内降解加工ADAMs的酶属依赖于Fe^3 或Zn^2 的蛋白水解酶。根据研究结果推测,体内许多不同性能的蛋白水解酶,如丝氨酸蛋白水解酶,半胱氨酸蛋白水解酶,天冬氨酸蛋白水解酶和金属蛋白水解酶等参与ADAMs的降解加工。     

ADAMs与哺乳动物受精

ADAMs是近几年发现的一类具有多个结构区和广泛生物学功能的糖蛋白,它们在哺乳动物受精中的作用日益得到实验结果的支持,本文简要总结了近几年ADAMs在哺乳动物受精中作用的研究进展。     

ADAMs参与哺乳动物精-卵结合与融合

ADAMs家族是含多结构域的跨膜蛋白。睾丸特异的ADAMs,在精子发生与附睾精子转运过程中,经过蛋白水解成为成熟精子的分子形式,与精．卵质膜结合和融合有关。对于精-卵质膜相互作用,ADAMs去整合素域具有关键氨基酸残基和特殊模体。模拟ADAM2和ADAM3去整合素域的短肽能用于鉴别特异性卵子识别蛋白。精子ADAMs去整合素域与卵子膜蛋白整合素β1、α4／α9、α6和CD9相互作用,介导了精卵质膜的结合与融合。     

ADAMs与哺乳动物受精

ADAMs是近几年发现的一类具有多个结构区和广泛生物学功能的糖蛋白,它们在哺乳动物受精中的作用日益得到实验结果的支持,本文简要总结了近几年ADAMs在哺乳动物受精中作用的研究进展。     

大鼠肝生长发育过程中蛋白水解酶和ADAMs的变化

用SDS-PAGE、SDS-G-PAGE、Western等方法研究了大鼠肝从胚胎到成体生长发育过程中酸性,中性和碱性蛋白水解酶和ADAMs变化。结果表明：30和32kD酸性蛋白水解酶在开始吃奶和出生后第五周各出现一个活性高峰;75/80kD酸性蛋白水解酶仅在出生后第三周有活性,71和75kD的中性蛋白酶在出生后第三周活性最强：15kD碱性蛋白水解酶在开始吃奶时有活性,75kD的ADAMs在出生前至出生后第20天和出生后第四周到成体的含量呈两次正态分布;40kD的ADAM主要在胚胎肝和吃奶时检测到,但30kDADAMs主要出现在吃饲料以后各个时期,50/47、73和140kDMDC15变化和75kD的ADAM相似,30kD的MDC15仅出现在出生后15-35天的肝脏内,58kD的MDC15主要在出生后7-45天之间,实验表明,营养来源和方式能有效影响肝脏的生理生化过程,揭示营养,肝功能,生长发育的密切关系。     

短间隔连续部分肝切除(SISPH)中ADAMs基因表达差异分析

用ADAMs通用引物进行RT PCR ,以检测短间隔连续部分肝切除 ( 4 3 6 3 6 3 6SPH)中不同恢复时间ADAMs基因转录情况。结果表明 :( 1)ADAMs基因转录无个体和性别差异 ,也无肝再生恢复期依赖性 ;( 2 )PCR产物克隆、测序证实 ,肝脏中有MDC9同源序列存在 ;( 3 )用MDC9特异性引物PCR检测表明 ,MDC9在正常和不同恢复时期肝脏中均有一定水平转录 ,说明MDC9在肝脏正常生理活动和肝再生中起重要作用     

离子交换层析初步分离大鼠肝蛋白水解酶、ADAMs、ACP、AKP和PCNA

用DEAE 离子交换层析法分离 2 /3肝切除 ( partialhepatectomy ,PH)后恢复 4、 3 6和 14 4h的大鼠再生肝及正常肝的蛋白水解酶、ADAMs、ACP、AKP和PCNA ;用SDS PAGE、Western blot、酶复性电泳等方法 ,分析了它们在不同洗脱段中的分布及活性变化 ,为分离与肝再生有关的蛋白 (酶 )提供了资料。     

常氏肝癌细胞cDNA文库的构建及ADAMs相关基因的免疫筛选与序列分析

抽提常氏肝癌细胞的总RNA,以oligo(dT)为引物,通过两次转换模板,采用LD-PCR合成全长cDNA,在cDNA两端引入SfiI的酶切位点。以λTriplEX2为载体经过包装后构建了常氏肝癌细胞cDNA表达文库。以ADAMs通用抗体,用免疫筛选技术从常氏肝癌cDNA文库中筛选出22个阳性克隆,经测序分析和BLAST检索,证实其中一个为新基因,部分区域具有蛋白酶的功能,对该基因进行了GenBank登录,获注册号为AY078070。该基因的克隆为研究ADAMs相关基因的功能奠定了基础。     

精子头后部质膜融合蛋白fertilin的研究进展

精子头后部(或赤道区)表面fertilin糖蛋白由相关的两个跨膜亚基α和β构成异二体形式。这两个亚基前体均含有金属蛋白酶区(met-alloprotease domain)和整联蛋白配体区(disin-tegrin domain),属于ADAMs gene家族。α和β前体分别在睾丸和附睾中从上述两区域连接处水解后,得到成熟型亚基。受精时,穿过透明带的顶体反应后精子借助β亚基的disintegrin肽段与卵母细胞表面的整联蛋白结合,同时fertilin结构发生变化,暴露出α亚基上潜在的融合肽段(90—111aa),并介导精子与卵母细胞发生质膜融合,最终完成受精过程。     

大鼠肝生长发育过程中蛋白水解酶和ADAMs的变化(英文)

用SDS-PAGE、SDS-G-PAGE、Western等方法研究了大鼠肝从胚胎到成体生长发育过程中酸性、中性和碱性蛋白水解酶和ADAMs变化。结果表明:30和32kD酸性蛋白水解酶在开始吃奶和出生后第五周各出现一个活性高峰;75/80kD酸性蛋白水解酶仅在出生后第三周有活性。71和75kD的中性蛋白酶在出生后第三周活性最强;15kD碱性蛋白水解酶在开始吃奶时有活性。75kD的ADAMs在出生前至出生后第20天和出生后第四周到成体的含量呈两次正态分布;40kD的ADAM主要在胚胎肝和吃奶时检测到,但30kD ADAMs主要出现在吃饲料以后各个时期;50/47、73和140kD MDC15变化和75kD的ADAM相似,30kD的MDC15仅出现在出生后15~35天的肝脏内,58kD的MDC15主要在出生后7~45天之间。实验表明,营养来源和方式能有效影响肝脏的生理生化过程,揭示营养、肝功能、生长发育的密切关系。     

ADAMs are present in fungi: identification of two novel ADAM genes in Aspergillus fumigatus

The ADAMs are a family of integral membrane proteases involved in shedding and fusion events in animal tissues. Here, we report the identification of two ADAMs, ADM-A and ADM-B, in the pathogenic fungus Aspergillus fumigatus. The domain structure of metazoan ADAMs was seen in ADM-A and -B, although with some differences. ADAMs were identified in other filamentous fungi and phylogenetic analysis indicated that the fungal ADAMs were monophyletic and most closely related to metazoan ADAM 10 and 17. Recombinant ADM-B protease specifically cleaved casein and albumin while recombinant propeptide+protease was inactive. A sheddase function is therefore proposed for fungal ADAMs.     

Multiple non-catalytic ADAMs are novel integrin α4 ligands

The ADAM (a disintegrin and metalloprotease) protein family uniquely exhibits both catalytic and adhesive properties. In the well-defined process of ectodomain shedding, ADAMs transform latent, cell-bound substrates into soluble, biologically active derivatives to regulate a spectrum of normal and pathological processes. In contrast, the integrin ligand properties of ADAMs are not fully understood. Emerging models posit that ADAM–integrin interactions regulate shedding activity by localizing or sequestering the ADAM sheddase. Interestingly, 8 of the 21 human ADAMs are predicted to be catalytically inactive. Unlike their catalytically active counterparts, integrin recognition of these “dead” enzymes has not been largely reported. The present study delineates the integrin ligand properties of a group of non-catalytic ADAMs. Here we report that human ADAM11, ADAM23, and ADAM29 selectively support integrin α4-dependent cell adhesion. This is the first demonstration that the disintegrin-like domains of multiple catalytically inactive ADAMs are ligands for a select subset of integrin receptors that also recognize catalytically active ADAMs.     

Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2

Defects in heart development are the most common congenital abnormalities in humans, providing a strong incentive to learn more about the underlying causes. Previous studies have implicated the metalloprotease-disintegrins ADAMs (a disintegrin and metalloprotease) 17 and 19 as well as heparin binding EGF-like growth factor (HB-EGF) and neuregulins in heart development in mice. Here, we show that mice lacking both ADAMs 17 and 19 have exacerbated defects in heart development compared to mice lacking either ADAM, providing the first evidence for redundant or compensatory functions of ADAMs in development. Moreover, we identified additional compensatory or redundant roles of ADAMs 9 and 19 in morphogenesis of the mitral valve and cardiac outflow tract. Cell biological studies designed to address the functions of these ADAMs in shedding of HB-EGF uncovered a contribution of ADAM19 to this process, but this was only evident in the absence of the major HB-EGF sheddase, ADAM17. In addition, ADAM17 emerged as the major sheddase for neuregulins beta1 and beta2 in mouse embryonic fibroblasts. These results raise the possibility that ADAMs 9, 17, and 19 contribute to heart development in humans and have implications for understanding the mechanisms underlying congenital heart disease.     

ADAMs: modulators of cell-cell and cell-matrix interactions

ADAMs contain adhesive and metalloprotease domains. As major ectodomain sheddases, they release a variety of cell-surface proteins, including growth factors, cytokines, cell adhesion molecules and receptors. ADAMs can also cleave and remodel components of the extracellular matrix. Hence, ADAMs are emerging as key modulators of cell-cell and cell-matrix interactions. Important questions, including if and how ADAM adhesive domains promote ADAM protease function, are currently being addressed.     

Preferred SH3 Domain Partners of ADAM Metalloproteases Include Shared and ADAM-Specific SH3 Interactions

A disintegrin and metalloproteinases (ADAMs) constitute a protein family essential for extracellular signaling and regulation of cell adhesion. Catalytic activity of ADAMs and their predicted potential for Src-homology 3 (SH3) domain binding show a strong correlation. Here we present a comprehensive characterization of SH3 binding capacity and preferences of the catalytically active ADAMs 8, 9, 10, 12, 15, 17, and 19. Our results revealed several novel interactions, and also confirmed many previously reported ones. Many of the identified SH3 interaction partners were shared by several ADAMs, whereas some were ADAM-specific. Most of the ADAM-interacting SH3 proteins were adapter proteins or kinases, typically associated with sorting and endocytosis. Novel SH3 interactions revealed in this study include TOCA1 and CIP4 as preferred partners of ADAM8, and RIMBP1 as a partner of ADAM19. Our results suggest that common as well as distinct mechanisms are involved in regulation and execution of ADAM signaling, and provide a useful framework for addressing the pathways that connect ADAMs to normal and aberrant cell behavior.     

Expression and relationship of male reproductive ADAMs in mouse

A number of a disintegrin and metalloprotease (ADAM) family members are expressed in mammalian male reproductive organs such as testis and epididymis. These reproductive ADAMs are divided phylogenically into three major groups: ADAMs 1, 4, 6, 20, 21, 24, 25, 26, 29, 30, and 34 (the first group); ADAMs 2, 3, 5, 27, and 32 (the second group); and ADAMs 7 and 28 (the third group). Previous mouse knockout studies indicate that ADAM1, ADAM2, and ADAM3 have intricate expressional relationships, playing critical roles in fertilization. In the present study, we analyzed processing, biochemical characteristics, localization, and expressional relationship of the previously-unexplored, second-group ADAMs (ADAM5, ADAM27, and ADAM32). We found that all of the three ADAMs are made as precursors in the testis and processed during epididymal maturation, and that ADAM5 and ADAM32, but not ADAM27, are located on the sperm surface. Using sperm from Adam2(-/-) and Adam3(-/-) mice, we found that, among the three ADAMs, the level of ADAM5 is modestly and severely reduced in Adam3 and Adam2 knockout sperm, respectively. Further, we analyzed ADAM7, an epididymis-derived sperm surface ADAM from the separate phylogenetic group, in the knockout sperm. We found that the level of ADAM7 is also significantly reduced in both Adam2 and Adam3-null sperm. Taken together, our results suggest a novel expressional relationship of ADAM5 and ADAM7 with ADAM2 and ADAM3, which play critical roles in fertilization.     

Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase

The putative alpha-secretase cleaves the amyloid precursor protein (APP) of Alzheimer's disease in the middle of the amyloid beta peptide (Abeta) domain. It is generally thought that the alpha-secretase pathway mitigates Abeta formation in the normal brain. Several studies have suggested that ADAM9, ADAM10, and ADAM17 are candidate alpha-secretases belonging to the ADAM (a disintegrin and metalloprotease) family, which are membrane-anchored cell surface proteins. In this comparative study of ADAM9, ADAM10, and ADAM17, we examined the physiological role of ADAMs by expressing these ADAMs in COS-7 cells, and both "constitutive" and "regulated" alpha-secretase activities of these ADAMs were determined. We tried to suppress the expression of these ADAMs in human glioblastoma A172 cells, which contain large amounts of endogenous alpha-secretase, by lipofection of the double-stranded RNA (dsRNA) encoding each of these ADAMs. The results indicate that ADAM9, ADAM10, and ADAM17 catalyze alpha-secretory cleavage and therefore act as alpha-secretases in A172 cells. This is the first report that to suggest the endogenous alpha-secretase is composed of several ADAM enzymes.     

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer.